Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 4Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 4Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × ravulizumab × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔